# SCTB41 Plus SCTB39G With or Without Standard Therapy in Advanced Solid Tumors

> **NCT07665970** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Sinocelltech Ltd.** · enrollment: 112 (estimated)

## Conditions studied

- Advanced Malignant Solid Tumors

## Interventions

- **DRUG:** SCTB41+SCTB39G

## Key facts

- **NCT ID:** NCT07665970
- **Lead sponsor:** Sinocelltech Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-30
- **Primary completion:** 2029-06-30
- **Final completion:** 2029-06-30
- **Target enrollment:** 112 (ESTIMATED)
- **Last updated:** 2026-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07665970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07665970, "SCTB41 Plus SCTB39G With or Without Standard Therapy in Advanced Solid Tumors". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07665970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*